Back to results
US 8,802,698 B2Granted
8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists
AssigneeTheravance Biopharma R&D IP, LLC
InventorsDaisuke Roland Saito, Daniel D. Long, Lan Jiang, Bryan Frieman
Life of this patent
Estimating the term…
Abstract
The invention provides 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds of formula (I): wherein R2, R7, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
Claims6
A compound selected from:
- a compound of the chemical formula
- which is denoted by the chemical name 3-endo-(8-{2-[((S)-2,3-dihydroxypropionyl)-(2-ethylbutyl)-amino]ethyl}-8-azabicyclo [3.2.1]oct-3-yl)-2-hydroxybenzamide, and
- a compound of the chemical formula
- which is denoted by the chemical name 3-endo-(8-2-[(4,4-difluoro-cyclohexylmethyl)-(2-methanesulfonyl-acetyl)-amino]-ethyl-8-aza-bicyclo [3.2.1]oct-3-yl)-2-hydroxy-benzamide;
- and
- pharmaceutically acceptable salts thereof.
3 more elements
Dependencies are inferred from the claim text.